Xolair and Emzumab: Affordable Omalizumab Options for Asthma and Chronic Hives Patients
For individuals dealing with severe allergic asthma or chronic spontaneous urticaria (hives), omalizumab has become a key therapy. Known by the brand name Xolair and the generic Emzumab, this biologic drug helps control symptoms where other medications fall short. However, high costs in the U.S. have pushed many patients to explore lower-priced alternatives—especially from India, where the same treatment can cost up to 87% less.
What Is Omalizumab?
Omalizumab is a monoclonal antibody that targets IgE (immunoglobulin E), a key immune system component responsible for triggering allergic responses. By binding to IgE, omalizumab prevents allergic reactions at the source, reducing inflammation, wheezing, and hives.
Brand and Generic Options
Xolair
- Chemical Name: Omalizumab
- Manufacturer: Novartis
- Country of Origin: India
- Dosage Form: 150mg vial (subcutaneous injection)
- Marketed as: Xolair (brand)
Emzumab
- Chemical Name: Omalizumab
- Manufacturer: Cipla Limited
- Country of Origin: India
- Dosage Form: 150mg vial (subcutaneous injection)
- Marketed as: Emzumab (biosimilar)
What Conditions Does It Treat?
- Moderate to Severe Allergic Asthma: For patients 6 years and older whose asthma is not well controlled with corticosteroids.
- Chronic Spontaneous Urticaria (CSU): For adults and adolescents who continue to experience hives despite antihistamine treatment.
Common Side Effects
Mild to Moderate:
- Pain, redness, or swelling at the injection site
- Headache
- Fatigue
- Upper respiratory tract infections
Serious (Less Common):
- Anaphylaxis (severe allergic reaction)
- Joint pain
- Rash
- Fever
- Increased vulnerability to parasitic infections
Patients are usually monitored for a short period after injection to detect rare but serious reactions like anaphylaxis.
Cost Savings: U.S. vs. India
Typical U.S. Pricing for Xolair 150mg Vial:
- $1,150 to $1,300 per vial (retail price at local U.S. pharmacies)
Pricing from India:
Estimated Savings:
- Buying Xolair from India: Save up to 80%
- Choosing Emzumab (Cipla): Save up to 87%
Conclusion: A Cost-Effective Lifeline
While omalizumab is highly effective, its cost can be a barrier for many. For those seeking the same treatment at a significantly lower price, Emzumab by Cipla and Indian-manufactured Xolair provide financially accessible options without compromising quality.
As always, patients should consult with their healthcare provider before switching to an international or biosimilar version to ensure safe and effective use.
This article has been viewed 37 times.